Showing results (151-160 of 389) with videos related to

Sort By:
Pageof 39
Cancer Science|April 27, 2018
Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trialHiroaki Akamatsu, Nobuyuki Katakami, Isamu Okamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2015
Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft modelHeyan Li, Shuo Wang, Koichi Takayama, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2020
NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migrationYuki Ikematsu, Kentaro Tanaka, Goji Toyokawa, et al.
Plos One|June 5, 2019
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinomaKazuki Takada, Mototsugu Shimokawa, Kensuke Tanaka, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505Isamu Okamoto, Takashi Nishimura, Masaki Miyazaki, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2014
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expressionHeyan Li, Koichi Takayama, Shuo Wang, et al.
European Journal of Cancer (Oxford, England : 1990)|May 5, 2009
Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancerKenji Tamura, Isamu Okamoto, Tomohiro Ozaki, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancerNoriko Hidaka, Eiji Iwama, Naoki Kubo, et al.
Clinical Lung Cancer|January 18, 2020
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC StudySuresh Senan, Isamu Okamoto, Gyeong-Won Lee, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2013
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumorsWataru Okamoto, Takayuki Yoshino, Toshiaki Takahashi, et al.
Pageof 39